Esperion Therapeutics, Inc. (NASDAQ: ESPR) today announced the appointment of Jeffrey Berkowitz, J.D. as a Class II Director, with a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE